Saad Usmani MD, MBBS, MBA, FACP, received his medical degree from Allama Iqbal Medical College Lahore, widely regarded as the top medical institution in Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, MI, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, CT. In 2020, Prof. Usmani completed a Masters of Business Administration at UNC Kenan-Flager Business School in Chapel Hill, NC.
Prof. Usmani has been with the Levine Cancer Institute in Charlotte, NC, since 2013 and holds the position of Director of Clinical Research in Hematologic Malignancies, and is the founding member and Division Chief of the plasma cell disorder program. He is also a Clinical Professor of Medicine at UNC School of Medicine in Chapel Hill, NC. Prof Usmani is a member of several professional societies, including the American Society of Hematology (ASH) and the International Myeloma Working Group. He is on the editorial review board of numerous medical journals and has authored/co-authored more than 130 peer-reviewed research manuscripts and 190 abstracts at national and international meetings.
Speaking on imaging and biomarkers in multiple myeloma
Prof. Usmani is a specialist in hematology, medical oncology and bone marrow transplantation. His clinical and translational research has been focused on plasma cell disorders, specifically high-risk multiple myeloma. Prof. Usmani is interested specifically in the prognostic role of multiple myeloma imaging and identifying mechanisms and biomarkers of resistance to novel agents in high-risk multiple myeloma.